By Dr Derek Jellinek
15 November 2023, 8:00 AM
Ramsay Health Care (ASX:RHC) investor day and site tour emphasised Australian operations and its digital ambitions, while the recent Asian JV sale helps jump-start B/S repair.
Read more...
By Dr Derek Jellinek
30 October 2023, 8:00 AM
ResMed Inc's (ASX:RMD) 1Q was broadly in line, with double-digit top-line growth and sequential improvement in operating leverage.
Read more...
By Dr Derek Jellinek
17 October 2023, 8:00 AM
The inaugural Capital Markets Day offered the opportunity to better understand the strategic direction across core franchises, vet the growing R&D portfolio and glimpse at information and digital initiatives.
Read more...
By Iain Wilkie
27 September 2023, 8:00 AM
Pro Medicus (ASX:PME) has signed its largest contract to date (by quite a distance), inking a A$140m contract over 10 years with a large US-based healthcare system.
Read more...
By Dr Derek Jellinek
25 August 2023, 8:30 AM
Ramsay Health Care's (ASX:RHC) FY23 results were mixed, with revenue gains across all regions on increased surgical activity, although margins and profit lagged.
Read more...
By Scott Power
24 August 2023, 8:00 AM
Ebos Group (ASX:EBO) reported another year of consistent earnings growth (up 14.1%) which benefitted from acquisitions in the medical technology and consumables category.
Read more...
By Emily Porter
23 August 2023, 9:00 AM
Monash IVF's (ASX:MVF) FY23 was in line with guidance of underlying NPAT of $25.5m (up 14.%).
Read more...
By Scott Power
23 August 2023, 8:00 AM
Nanosonics' (ASX:NAN) FY23 results came in at the top end of guidance however focus centred around timing of CORIS®, which has been delayed by at least six months. Disappointing, but not unsurprising.
Read more...
By Dr Derek Jellinek
18 August 2023, 10:00 AM
Sonic Healthcare's (ASX:SHL) FY23 results were mixed, as Covid-19-related costs remained elevated, impacting profitability, while revenue was broadly in-line.
Read more...
By Dr Derek Jellinek
16 August 2023, 8:00 AM
CSL Ltd's (ASX:CSL) FY23 results were in line with the pre-release at the top of guidance, with underlying net profit up double-digits on strong sales growth across all segments.
Read more...